Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.52 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237213 | 0.94 | PIK3CA (0.54) | PIK3CAPIK3CBPIK3CGSTAT6 | |
| SCHEMBL2235916 | 0.93 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CGSTAT6 | |
| SCHEMBL2305053 | 0.91 | HRH4 (0.44) | PIK3CAPIK3CBPIK3CGFYN | |
| SCHEMBL2241522 | 0.89 | PIK3CA (0.47) | PIK3CAPIK3CBPIK3CGPLK4 | |
| SCHEMBL2239595 | 0.87 | PIK3CA (0.50) | PIK3CAPIK3CBPIK3CG | |
| SCHEMBL2237778 | 0.86 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CG | |
| SCHEMBL2237808 | 0.86 | PIK3CA (0.47) | PIK3CAPIK3CBPIK3CGPLK4 | |
| SCHEMBL2237617 | 0.83 | CFTR (0.41) | PIK3CA | |
| SCHEMBL2241125 | 0.82 | HRH4 (0.53) | FYN | |
| SCHEMBL2241140 | 0.82 | NPSR1 (0.44) | PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | claimed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | claimed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | PIK3CA 222/4885PIK3CB 536/4885PIK3CG 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.